Alexander Friedman, PA
Physician Assistant · Watsonville, CANPI 1730621848
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,728 and has fallen 97.2% since, to $49 in 2025. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$770
- Lilly USA, LLC$557
- Novo Nordisk$543
- Bayer$453
- GSK$406
- Amgen$273
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,536100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $770 |
| Lilly USA, LLC | 41 | $557 |
| Novo Nordisk | 29 | $543 |
| Bayer | 22 | $453 |
| GSK | 25 | $406 |
| Amgen(2 entities) | 17 | $273 |
| Idorsia Pharmaceuticals US Inc | 10 | $216 |
| Pfizer | 11 | $186 |
| Mylan Specialty L.p. | 7 | $165 |
| AstraZeneca | 8 | $134 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $121 |
| Sanofi-aventis U.S. LLC | 6 | $118 |
| Abbott | 4 | $93 |
| Biohaven Pharmaceuticals, Inc. | 4 | $83 |
| Boehringer Ingelheim | 5 | $77 |
| E.r. Squibb & Sons, L.L.C. | 5 | $75 |
| Radius Health, Inc. | 3 | $70 |
| Viiv Healthcare Company | 2 | $29 |
| Johnson & Johnson | 2 | $26 |
| Myriad Women's Health, Inc. | 1 | $26 |
| Smith+Nephew | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Organon | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$4,536 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 36 | $48,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $23,027 |
| EliquisApixaban | 20 | $19,170 |
| OzempicSemaglutide | 18 | $15,628 |
| TrulicityDulaglutide | 12 | $11,790 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,262 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $2,287 |
| Atorvastatin Calcium | 143 | $1,882 |
| Rosuvastatin Calcium | 75 | $1,559 |
| Lidocaine | 18 | $1,290 |
| Pantoprazole Sodium | 40 | $964 |
| Ventolin HfaAlbuterol Sulfate | 13 | $719 |
| Propranolol Hcl ErPropranolol Hcl | 15 | $715 |
| Levothyroxine Sodium | 57 | $709 |
| Tamsulosin Hcl | 47 | $690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $77 | $48,00036 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $406 | $28,29044 claims |
| PfizerEliquis | $186 | $19,17020 claims |
| Novo NordiskOzempic | $543 | $15,62818 claims |
| Lilly USA, LLCTrulicity | $557 | $11,79012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Watsonville
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Andrea FoxStanford$172K
- Asma HussainiThousand Oaks$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.